Novartis remibrutinib Phase 3 results in relapsing multiple sclerosis, highlighting BTK inhibition, B-cell signaling and neuroinflammation.

Novartis Remibrutinib Delivers Two Phase 3 Wins in Relapsing Multiple Sclerosis

The oral BTK inhibitor significantly reduced annualized relapse rates versus teriflunomide in both REMODEL-1 and REMODEL-2, with no liver safety signal reported across the two pivotal studies.


Key Takeaways

  • Novartis reported positive topline results from both Phase 3 REMODEL-1 and REMODEL-2 trials of remibrutinib in relapsing multiple sclerosis (RMS).
  • Remibrutinib significantly reduced annualized relapse rate versus teriflunomide in approximately 2,000 adults with RMS, while also improving key MRI measures of inflammatory disease activity.
  • Novartis reported no liver safety signal and no cases meeting Hy’s Law criteria, a potentially important differentiator within the competitive BTK inhibitor class.

Data Snapshot

ItemDetails
DrugRemibrutinib
CompanyNovartis
MechanismOral BTK inhibitor
IndicationRelapsing multiple sclerosis
PhasePhase 3
TrialsREMODEL-1 / REMODEL-2
EnrollmentApproximately 2,000 adults
ComparatorTeriflunomide
Primary endpointAnnualized relapse rate
Primary resultBoth Phase 3 trials positive
DisabilityPositive 3mCDP trend; nominally significant 6mCDP
Liver safetyNo signal; no Hy’s Law cases
Next stepGlobal regulatory submissions planned

In the Phase 3 REMODEL-1 and REMODEL-2 trials, remibrutinib significantly reduced annualized relapse rate versus teriflunomide in approximately 2,000 adults with relapsing multiple sclerosis. (Novartis REMODEL)


What Happened

Novartis announced on September 1, 2026, that the identical Phase 3 REMODEL-1 and REMODEL-2 trials both met their primary endpoint. Remibrutinib demonstrated superiority over teriflunomide in reducing annualized relapse rate and also met key secondary endpoints measuring inflammatory brain lesions on MRI. (Novartis Phase 3)

In a preplanned combined analysis, remibrutinib showed a positive trend in 3-month confirmed disability progression (3mCDP) and nominal statistical significance for 6-month confirmed disability progression (6mCDP). Full numerical results are expected to be presented at MSToronto2026.

The safety readout may be particularly important. Novartis reported no liver safety signal and no cases meeting Hy’s Law criteria across REMODEL-1 and REMODEL-2. This contrasts with liver-safety concerns that have affected other BTK inhibitor programs in multiple sclerosis. (Fierce Pharma)

Reuters also highlighted the commercial significance of the readout, noting analyst expectations that remibrutinib could eventually generate multibillion-dollar peak sales across multiple indications if its broader development program succeeds. (Reuters)


Why It Matters

Multiple sclerosis treatment already includes highly effective therapies such as anti-CD20 antibodies, but these drugs primarily work by depleting B cells.

Remibrutinib takes a different approach. It inhibits Bruton’s tyrosine kinase (BTK), an intracellular signaling protein involved in the activation of B cells and innate immune cells, including macrophages and microglia. BTK inhibition therefore has the potential to suppress both peripheral adaptive immune activity and myeloid-cell-driven neuroinflammation without directly eliminating the B-cell compartment. (Novartis BTK mechanism)

The competitive bar is already high. Roche’s fenebrutinib reduced annualized relapse rate by 51.1% and 58.5% versus teriflunomide in the Phase 3 FENhance 1 and 2 trials, respectively, and has also generated positive Phase 3 results in primary progressive MS. (Roche fenebrutinib)

Sanofi’s tolebrutinib (Cenrifki) is already approved in the European Union for secondary progressive MS without relapses in the previous two years. Its brain-penetrant profile is designed to target CNS-resident inflammatory cells, although drug-induced liver injury remains an identified safety risk. (Sanofi Cenrifki)

The figure above highlights the mechanistic distinction between BTK inhibition and anti-CD20 therapy in multiple sclerosis. Remibrutinib suppresses intracellular BTK signaling downstream of B-cell and Fc receptors, potentially reducing immune activation in both B cells and myeloid or microglial cells while largely preserving the B-cell population. By contrast, anti-CD20 antibodies such as Ocrevus and Kesimpta reduce CD20-positive B cells directly, making B-cell depletion rather than signaling suppression their primary therapeutic strategy.


BP View

Remibrutinib’s Phase 3 success matters because Novartis has now demonstrated efficacy in two independent pivotal RMS trials, substantially strengthening the regulatory case ahead of planned global submissions.

The liver-safety result may become equally important. BTK inhibitors have faced repeated development setbacks related to hepatotoxicity, while REMODEL reported no liver safety signal and no Hy’s Law cases. If this profile holds in the full dataset and longer follow-up, safety could become one of remibrutinib’s strongest competitive advantages.

Competition will nevertheless be intense. Fenebrutinib has already shown strong relapse reduction in RMS and positive Phase 3 results in PPMS, while tolebrutinib has differentiated itself through CNS penetration and an approved progressive-MS indication in Europe. Remibrutinib therefore needs to compete not simply as another BTK inhibitor, but through the overall balance of relapse control, disability benefit, CNS activity and long-term safety.

In my view, the next major catalyst is the full REMODEL dataset. The magnitude of ARR reduction, confirmed disability outcomes and longer-term safety will determine whether remibrutinib can challenge both competing BTK inhibitors and established anti-CD20 therapies in the MS market.

[Insert final body image here]


Related Post

For another recent example of targeted immunology moving toward more selective control of immune signaling, read my previous analysis of Priovant’s Lisraya approval in dermatomyositis.


About BP

Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.

Have a different view on this analysis or another angle you’d like to discuss? Leave a comment — I’d be happy to hear your thoughts.


Comments

3 responses to “Novartis Remibrutinib Delivers Two Phase 3 Wins in Relapsing Multiple Sclerosis”

  1. […] Want the news story behind this science? Read my analysis of Novartis’ positive Phase 3 REMODEL results for remibrutinib in relapsing multiple sclerosis. […]

  2. […] Novartis Remibrutinib Delivers Two Phase 3 Wins in Relapsing Multiple Sclerosis […]

  3. […] For another recent example of selective immune signaling control, read my previous analysis of Novartis’ remibrutinib Phase 3 results in relapsing multiple sclerosis. […]

Leave a Reply